U 89678 | CAS#157744-31-5

MedKoo Cat#: 462845 | Name: U 89678

Description:

WARNING: This product is for research use only, not for human or veterinary use.

U 89678 is a tirilazad mesylate metabolite that has protective effects against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.

Chemical Structure

U 89678

CAS#157744-31-5

Theoretical Analysis

MedKoo Cat#: 462845

Name: U 89678

CAS#: 157744-31-5

Chemical Formula: C38H54N6O2

Exact Mass: 626.4308

Molecular Weight: 626.89

Elemental Analysis: C, 72.81; H, 8.68; N, 13.41; O, 5.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

U-89678; U89678;

IUPAC/Chemical Name

(5R,8S,10R,13S,14S,16R,17S)-17-(2-(2-(2,6-di(pyrrolidin-1-yl)pyrimidin-4-yl)piperazin-1-yl)acetyl)-10,13,16-trimethyl-4,5,6,7,8,10,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one

InChi Key

XJKDZKQCLJIYNZ-UVBXRMJNSA-N

InChi Code

InChI=1S/C38H54N6O2/c1-25-20-30-28-9-8-26-21-27(45)10-12-37(26,2)29(28)11-13-38(30,3)35(25)33(46)24-44-19-14-39-23-32(44)31-22-34(42-15-4-5-16-42)41-36(40-31)43-17-6-7-18-43/h10-12,22,25-26,28,30,32,35,39H,4-9,13-21,23-24H2,1-3H3/t25-,26-,28-,30+,32?,35-,37+,38+/m1/s1

SMILES Code

C[C@@H]1C[C@H]2[C@@H]3CC[C@@H]4CC(C=C[C@@]4(C3=CC[C@@]2([C@H]1C(CN5CCNCC5c6nc(N7CCCC7)nc(N8CCCC8)c6)=O)C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 626.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Smith SL, Scherch HM, Hall ED. Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J Neurosurg. 1996 Feb;84(2):229-33. doi: 10.3171/jns.1996.84.2.0229. PMID: 8592225. 2: Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad. J Clin Pharmacol. 1996 Sep;36(9):809-13. doi: 10.1002/j.1552-4604.1996.tb04254.x. PMID: 8889901. 3: Fleishaker JC, Straw RN, Cross CJ. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. J Pharm Sci. 1997 Apr;86(4):434-7. doi: 10.1021/js960410e. PMID: 9109044. 4: Wienkers LC, Steenwyk RC, Hauer MJ, Fleishaker JC, Pearson PG. Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2. J Pharmacol Exp Ther. 1998 Nov;287(2):583-90. PMID: 9808684. 5: Fleishaker JC, Hulst-Pearson LK, Peters GR. Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects. Am J Ther. 1995 Aug;2(8):553-560. doi: 10.1097/00045391-199508000-00007. PMID: 11854826. 6: Fleishaker JC, Pearson LK, Peters GR. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur J Clin Pharmacol. 1996;50(1-2):139-45. doi: 10.1007/s002280050082. PMID: 8739825. 7: Fleishaker JC, Hulst LK, Peters GR. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther. 1994 Oct;56(4):389-97. doi: 10.1038/clpt.1994.153. PMID: 7955800. 8: Fleishaker JC, Hulst LK, Peters GR. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Int J Clin Pharmacol Ther. 1994 May;32(5):223-30. PMID: 7921515. 9: Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Int J Clin Pharmacol Ther. 1997 Jan;35(1):28-32. PMID: 9021439. 10: Fleishaker JC, Pearson LK, Peters GR. Induction of tirilazad clearance by phenytoin. Biopharm Drug Dispos. 1998 Mar;19(2):91-6. doi: 10.1002/(sici)1099-081x(199803)19:2<91::aid-bdd78>3.0.co;2-t. PMID: 9533108. 11: Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation. J Pharmacol Exp Ther. 1998 Nov;287(2):591-7. PMID: 9808685. 12: Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther. 1996 May;277(2):991-8. PMID: 8627582. 13: Bombardt PA, Brewer JE, Johnson MG. Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. J Pharmacol Exp Ther. 1994 Apr;269(1):145-50. PMID: 8169818. 14: Pearson LK, Fleishaker JC, Peters GR. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Eur J Clin Pharmacol. 1996;50(4):299-304. doi: 10.1007/s002280050112. PMID: 8803523.